Lupin Limited today announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, as a generic equivalent to Sunovion Pharmaceuticals, Inc.’s Latuda Tablets.
In the United States, Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg (RLD Latuda) had an estimated annual sales of USD 4.2 billion, as per IQVIA MAT December 2022.
Lupin develops and commercializes a varied range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including India, the United States, South Africa, Latin America (LATAM), Asia Pacific (APAC), Europe, and the Middle East.
In FY22, the company spent 8.7% of its revenue on research and development.
At around 2.44 PM, Lupin was trading at Rs668.80, up by 0.25% against the previous close of Rs667.10 on NSE. The counter touched an intraday high and low of Rs674.05 and Rs662.25 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
